Abstract
Objectives To develop a new interface for the widely used prognostic breast cancer tool: PREDICT. To facilitate shared decision-making around post-surgery breast cancer treatments. To derive insights into communicating the outputs of prognostic models to patients and their clinicians.
Method We applied user-centred design principles in developing a new interface for PREDICT. The research involved online surveys, focus groups, meetings, and usability testing with patients, clinicians and the public.
Results The new interface has been launched and delivers around 30,000 sessions per month. We identified several principles that are useful when communicating the output of prognostic models, including multiple presentation formats, and contextualising statistics. A programme of future work based on patient and clinician feedback has been developed, including the provision of quantitative data on the adverse effects of adjuvant breast cancer treatments.
Conclusions For prognostic algorithms to fulfil their potential to assist with shared decision-making they need carefully designed interfaces. User-centred design puts patients and clinicians needs at the forefront, allowing them to derive the maximum benefit from prognostic models.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the David and Claudia Harding Foundation. GF was also supported by a Wellcome ISSF award (204796/Z/16/Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the University of Cambridge Psychology Research Ethics Committee (PRE.2016.103).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.